Industry sponsorship and research outcome (Q24202591)

Andreas Lundh

1

0 references

Joel Lexchin

3

Joel Lexchin

0 references

Octavian A Busuioc

4

Octavian A Busuioc

0 references

Sergio Sismondo

2

Cochrane Database of Systematic Reviews

Sergio Sismondo

0 references

language of work or name

English

0 references

publication date

12 December 2012

0 references

published in

0 references

volume

12

0 references

page(s)

MR000033

0 references

cites work

Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Bias from industry trial funding? A framework, a suggested approach, and a negative result

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Evolution of the randomized controlled trial in oncology over three decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association of industry sponsorship to published outcomes in gastrointestinal clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Industry sponsorship and authorship of clinical trials over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Funding source, trial outcome and reporting quality: are they related? Results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Assessment of risk of bias among pediatric randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association of funding and findings of pharmaceutical research at a meeting of a medical professional society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Epidemiologic studies of adverse effects of anti-retroviral drugs: how well is statistical power reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

A comparison of the scientific quality of publicly and privately funded randomized controlled drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Relationship between drug company funding and outcomes of clinical psychiatric research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Third generation oral contraceptives and risk of venous thrombosis: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The relationship between the outcome of studies of autologous chondrocyte implantation and the presence of commercial funding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association between research sponsorship and study outcome in plastic surgery literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Adverse effects of inhaled corticosteroids in funded and nonfunded studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The quality of reporting of randomized controlled trials in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Extent and impact of industry sponsorship conflicts of interest in dermatology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Relationship between sponsorship and failure rate of dental implants: a systematic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association of trial registration with the results and conclusions of published trials of new oncology drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Factors associated with results and conclusions of trials of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Quality of reporting of randomized controlled trials in general endocrinology literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Influence of drug company authorship and sponsorship on drug trial outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Glucosamine for pain in osteoarthritis: why do trial results differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Relationship between conflicts of interest and research results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Publication bias in the medical literature: a review by a Canadian Research Ethics Board

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Randomized clinical trials in HEPATOLOGY: predictors of quality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Factors associated with failure to publish large randomized trials presented at an oncology meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Characteristics associated with citation rate of the medical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Quality of randomized controlled trials reporting in the primary treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association between funding source and study outcome in orthopaedic research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The influence of industry sponsorship on the acceptance of abstracts and their publication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Randomized trials stopped early for benefit: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Randomized trials assessing calcium supplementation in healthy children: relationship between industry sponsorship and study outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Nonscientific factors associated with acceptance for publication in The Journal of Bone and Joint Surgery (American Volume).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Is research presented at the scoliosis research society annual meeting influenced by industry funding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Frequency and determinants of nonpublication of research in the stroke literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Industry support and correlation to study outcome for papers published in Spine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Industry funding and the reporting quality of large long-term weight loss trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Randomized controlled trials in otolaryngology journals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The association between funding by commercial interests and study outcome in randomized controlled drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Influences on the quality of published drug studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The importance of independent academic statistical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Funding of US biomedical research, 2003-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Rethinking credible evidence synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Comparison of protocols and registry entries to published reports for randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The Haunting of Medical Journals: How Ghostwriting Sold “HRT”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

All clinical trials must be reported in detail and made publicly available

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

21 January 2018

We want raw data, now

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Metabias: a challenge for comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Why we need easy access to all data from all clinical trials and how to accomplish it

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Industry sponsorship and selection of comparators in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Comparison of registered and published primary outcomes in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting bias in medical research - a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Agreement among reviewers of review articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Results of clinical trials sponsored by for-profit vs nonprofit entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Design and reporting modifications in industry-sponsored comparative psychopharmacology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Pharmaceutical company funding and its consequences: a qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Narrative review: the promotion of gabapentin: an analysis of internal industry documents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Disclosure of competing financial interests and role of sponsors in phase III cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

Lack of Head-to-head Trials and Fair Control Arms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Minimizing bias in randomized trials: the importance of blinding

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Results of clinical trials sponsored by for-profit vs nonprofit entities

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Association between pharmaceutical involvement and outcomes in breast cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Source of funding and outcome of clinical trials

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Use and sources of medical knowledge

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

How pharmaceutical industry funding affects trial outcomes: causal structures and responses

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

The uncertainty principle and industry-sponsored research

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Sponsorship, authorship, and accountability

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

The unobtainable placebo: control of independent clinical research by industry?

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Conflict of Interest in the Debate over Calcium-Channel Antagonists

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Factors associated with publication following presentation at a transplantation meeting

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Differential citation rates of major cardiovascular clinical trials according to source of funding: a survey from 2000 to 2005

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Conflict of interest in orthopaedic research. An association between findings and funding in scientific presentations

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

Manufacturer support and outcome.

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021

The quality of drug studies published in symposium proceedings

1 reference

https://api.crossref.org/works/10.1002/14651858.MR000033.PUB2

7 January 2021